Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib

References

• Chabrol F, David P-M, Krikoriand G. Rationing hepatitis C treatment in the context of austerity policies in France and Cameroon: a transnational perspective on the pharmaceuticalization of healthcare systems. Soc Sci Med. 2017;187:243–245 https://doi.org/10.1016/j.socscimed.2017.03.059.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global report on access to hepatitis C treatment. Geneva: World Health Organization; 2016.
   Google Scholar
• European Commission. Joint report on health care and long-term care systems & fiscal sustainability, volume 1. Brussels: European Commission; 2016.
   Google Scholar
• Council of the European Union. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States (2016/C 269/06). Luxembourg: OJ C269/31; 2016.
   Google Scholar
• European Federation of Pharmaceutical Industries and Associations. EFPIA statement on the Commission’s proposal to introduce an SPC manufacturing waiver, weakening Europe’s knowledge based economy. 25 May 2018. Available from: https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/28052018-efpia-statement-on-the-commission-s-proposal-to-introduce-an-spc-manufacturing-waiver-weakening-europe-s-knowledge-based-economy/. Accessed 11 Dec 2019.
   Google Scholar
• Hitchcock J, Tugal B. The latest thinking on best strategies on use of supplementary certificates. Int J Med Mark. 2003;3:220–225.
   Google Scholar
• Howard Leighton. Strategic use of supplementary protection certificates. Journal of Generic Medicines. 2009;6:284–291. https://doi.org/10.1057/jgm.2010.17. Accessed 11 Dec 2019.
   Google Scholar
• Whitehead B, Jackson S, Kempner R. Managing generic competition and patent strategies in pharmaceutical industry. J Intellect Property Law Pract. 2008;3:226–235.
   Google Scholar
• Mazer EH. Supplementary protection certificates in the European economic community. Food Drug Law J. 1993;48:571-6.
   Google Scholar
• Medicines for Europe. Supplementary protection certificates: manufacturer waiver – benefits & myths. Brussels: Medicines for Europe; 2017.
   Google Scholar
• European Union. Regulation (EU) 2019/933 amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products. Luxembourg: OJ L153/1; 2019.
   Google Scholar
• Collis H. Drug lobby’s market protections. Brussels: Politico; 10 May 2017.
   Google Scholar
• Médecins Sans Frontières. Open submission on supplementary protection certificates for medicinal products in the European Union. 2017.
   Google Scholar
• Max Planck Institute. Study on the legal aspects of supplementary protection certificates in the EU. Luxembourg: European Commission; 2018.
   Google Scholar
• Copenhagen Economics. Study of the economic impact of supplementary protection certificates, pharmaceutical incentives and rewards. Luxembourg: European Commission; 2018.
   Google Scholar
• Charles Rivers Associates. Assessing economic impact of changing exemption provisions during patent and SPC protection in Europe. Luxembourg: European Commission; 2017.
   Google Scholar
• Mejer M. 25 years of SPC protection for medicinal products in Europe: insights and challenges. Luxembourg: European Commission; 2017.
   Google Scholar
• Kyle M. Economic analysis of supplementary protection certificates in Europe. Luxembourg: European Commission; 2017.
   Google Scholar
• The Council of the European Communities. Regulation (EEC) 1768/92 concerning the creation of a supplementary protection certificate for medicinal products. Luxembourg: OJ L182/1; 1992.
   Google Scholar
• May CH, Sell SK. Intellectual property: a critical history. Boulder: Lynne Rienner; 2006.
   Google Scholar
• Löfgren H, Williams O. The new political economy of pharmaceuticals: conformity and resistance in the global south. In: Löfgren H, Williams O, editors. The new political economy of pharmaceuticals: production, innovation and TRIPS in the global south. London: Palgrave 2013. p. 1–28.
   Google Scholar
• World Trade Organization, Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1869 UNTS 299, 33 ILM 1197 (1994). Marrakesh. 1994.
   Google Scholar
• Drahos P, Braithwaite J. Hegemony based on knowledge: the role of intellectual property. In: Chen J, Walker G, editors. Balancing act: law, policy and politics in globalisation and global trade. Annandale: Federation Press; 2004. p. 204–223.
   Google Scholar
• World Health Organization. Access to medicines. WHO Drug Inf. 2005;19:236–241.
   Google Scholar
• United States Congress. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98–417; Washington D.C. 1984.
   Google Scholar
• United States Code. Title 35-Patents, Part II, Chapter 14-Issue of Patent, §156 Extension of patent term, 35 USC §156. United States. 2015.
   Google Scholar
• Engelberg A. Special patent provisions for pharmaceuticals: Have they outlived their usefulness? A political legislative and legal history of U.S. law and observations for the future. J Law Technology. 1999;39:389–435.
   Google Scholar
• LOI no 90-510 du 25 juin 1990 tendant à rendre identique, pour les médicaments et les autres produits, la durée effective de la protection assurée par les brevets. JORF n°147 du 27 juin 1990 page 7488.
   Google Scholar
• L. 19 ottobre 1991, n. 349. Disposizioni per il rilascio di un certificato complementare di protezione per i medicamenti o i relativi componenti, oggetto di brevetto.
   Google Scholar
• Dylst Pieter, Vulto Arnold, Simoens Steven. Overcoming challenges in market access of generic medicines in the European Union. Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector. 2012;9(1):21–28https://doi.org/10.1177/1741134312441107. Accessed 11 Dec 2019.
   Google Scholar
• El-Said H, El-Said M. TRIPS-plus implications for access to medicines in developing countries: lessons from Jordan–United States free trade agreement. J World Intellect Property. 2007;10:438–475.
   Google Scholar
• Akaleephan Chutima, Wibulpolprasert Suwit, Sakulbumrungsil Rungpetch, Luangruangrong Paithip, Jitraknathee Anchalee, Aeksaengsri Achara, et al. Extension of market exclusivity and its impact on the accessibility to essential medicines, and drug expense in Thailand: Analysis of the effect of TRIPs-Plus proposal. Health Policy. 2009;181:174–182. https://doi.org/10.1016/j.healthpol.2008.12.009. Accessed 11 Dec 2019.
   Google Scholar
• Harris T, Nicol D, Gruen N. Pharmaceutical patent review report. Canberra: IP Australia; 2013.
   Google Scholar
• European Union. Canada–European Union Comprehensive Economic and Trade Agreement Implementation Act. Luxembourg: OJ L11/23; 2017.
   Google Scholar
• Bagnoli P, Busbyl C. Patent restoration and the cost of pharmaceuticals. Ottawa: Office of the Parliamentary Budgetary Officers of Canada; 2018.
   Google Scholar
• European Union. Regulation (EC) 469/2009 concerning the supplementary protection certificate for medicinal products. Luxembourg: OJ L152/1; 2009.
   Google Scholar
• Grabowski Henry G, Vernon John M. Effective patent life in pharmaceuticals. International Journal of Technology Management. 2000;19:98–120. https://doi.org/10.1504/IJTM.2000.002803. Accessed 11 Dec 2019.
   Web of Science ®Google Scholar
• European Parliament. Resolution on EU options for improving access to medicines (2016/2057(INI)), 2017.
   Google Scholar
• Ricciardi W, Barros PP, Bourek A, Brouwer W, Lehtonen L, McKee M, et al. Innovative payment models for high-cost innovative medicines – Report of the Expert Panel on effective ways of investing in Health. Luxembourg: European Commission; 2018.
   Google Scholar
• de Jongh T, Radauer A, Bostyn S, Poort J. Effects of supplementary protection mechanisms for pharmaceutical products. Amsterdam: Technopolis Group; 2018.
   Google Scholar
• European Commission. Impact assessment – Proposal for a Regulation of the European Parliament and of the Council amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products. SWD (2018) 240 final. Brussels: European Commission; 2018.
   Google Scholar
• Harris R. R&D Costs For Cancer Drugs Are Likely Much Less Than Industry Claims, Study Finds: Washington: NPR; 2017.
   Google Scholar
• Médecins Sans Frontières. Lives on the Edge: Time to align medical research and development with people’s health needs. 2016.
   Google Scholar
• Prasad V, Mailankody S. Research and Development spending to bring a single Cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569–1575.
   PubMed Web of Science ®Google Scholar
• Adams Christopher, Brantner Van V. Estimating The Cost Of New Drug Development: Is It Really $802 Million? Health Affairs Market Watch. 2006;25. https://doi.org/10.1377/hlthaff.25.2.420. Accessed 11 Dec 2019.
   Google Scholar
• DiMasi Joseph, Grabowski Henry, Hansen Ronald. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016;47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012. Accessed 11 Dec 2019.
   PubMed Web of Science ®Google Scholar
• Gilead. Fourth quarter and full year financial results 2004–2017. Available from: https://www.gilead.com/news/press-releases/. Accessed 11 Dec 2019.
   Google Scholar
• Roche. Financial reports 2004–2017. Available from: https://www.roche.com/investors/downloads.htm. Accessed 11 Dec 2019.
   Google Scholar
• Novartis. Annual reports 2004–2017. Available from: https://www.novartis.com/investors/novartis-annual-reporting-suite/annual-report-and-20-f-archive#ui-id-3=1. Accessed 11 Dec 2019.
   Google Scholar
• Morris C. America’s most expensive prescription drugs New Jersey: CNBC; 2017.
   Google Scholar
• Krauskopf L, Basu A. Gilead bets $11billion on hepatitis in Pharmasset deal. New York: Reuters; 2011.
   Google Scholar
• Gilead. Press Release: U.S. Food and Drug Administration approves Gilead’s Sovaldi™ (Sofosbuvir) for the treatment of chronic hepatitis C. 6 December 2013. Available from: https://www.gilead.com/news-and-press/press-room/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c. Accessed 11 Dec 2019.
   Google Scholar
• Sovaldi (sofosbuvir). An overview of Sovaldi and why it is authorised in the EU. London: European Medicines Agency; 2019.
   Google Scholar
• European Patent Register, EP2203462 (Gilead. Nucleoside phosphoramidate prodrugs). Munich. 2014. https://register.epo.org/application?number=EP08732818&lng=en&tab=main. Accessed 11 Dec 2019.
   Google Scholar
• European Patent Register, EP2604620 (Gilead. Modified fluorinated nucleoside analogues). Munich. 2016. https://register.epo.org/application?number=EP13152340. Accessed 11 Dec 2019.
   Google Scholar
• National Industrial Property Institute of France, Supplementary Protection Certificate FR14C0082. https://bases-brevets.inpi.fr/en/document-en/FR14C0082.html?p=5&s=1576078625187&cHash=1775515fafe3642917f44bedbd6dc29e. Accessed 11 Dec 2019.
   Google Scholar
• Swedish Patent Database, Supplementary Protection Certificate SE 1490066–6. https://was.prv.se/spd/search?tab=4&lang=en. Accessed 11 Dec 2019.
   Google Scholar
• The State Patent Bureau of the Republic of Lithuania, Supplementary Protection Certificate C2203462/PA2014040. https://www.vpb.lt/db_eu_patentai/papildoma_apsauga.php?db=vpb_europat&idappli=X1250046&extidpatent_old=2203462&extidappli_pagr=08732818.3&id=. Accessed 11 Dec 2019.
   Google Scholar
• Industrial Property Office of the Slovak Republic, Supplementary Protection Certificate PDO5029-2014. https://wbr.indprop.gov.sk/WebRegistre/DodatkoveOchranneOsvedcenie/Detail/5029-2014. Accessed 11 Dec 2019.
   Google Scholar
• Vasella D. Magic cancer bullet: how a tiny orange pill is rewriting medical history. Harper Collins: New York; 2003.
   Google Scholar
• Jones Gregory H, Carrier Michael A, Silver Richard T, Kantarjian Hagop. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016;127:1398–1402. https://doi.org/10.1182/blood-2015-11-680058. Accessed 11 Dec 2019.
   PubMed Web of Science ®Google Scholar
• European Patent Register, EP0564409 (Novartis. Pyrimidin derivatives and process of their preparation). Munich. 2000. https://register.epo.org/application?number=EP93810219&tab=main. Accessed 11 Dec 2019.
   Google Scholar
• Oosting B, van den Bos H. The Hague court confirms paediatric extension of SPC for former EU orphan drug imatinib: Lexology 2016. Available from: https://www.lexology.com/library/detail.aspx?g=c45e5f48-de26-46f6-afc8-8c13c2eabb63. Accessed 11 Dec 2019.
   Google Scholar
• National Industrial Property Institute of France, Supplementary Protection Certificate FR02C0012 (Novartis. Imatinib mesilate). France. 2014. https://bases-brevets.inpi.fr/en/document-en/FR02C0012.html?p=5&s=1576080671877&cHash=9608a45d568e01d4bbcefd69ae640561. Accessed 11 Dec 2019.
   Google Scholar
• Genentech. Press Release: Roche and Genentech sign licensing agreement for Herceptin. 1998. Available from: https://www.gene.com/media/press-releases/4778/1998-07-06/roche-and-genentech-sign-licensing-agree. Accessed 11 Dec 2019.
   Google Scholar
• Genentech. Press Release: 2nd Quarter Results. 1998. Available from: https://www.gene.com/media/press-releases/4777/1998-07-14/genentech-reports-1998-2nd-quarter-resul. Accessed 11 Dec 2019.
   Google Scholar
• Roche. Annual report: KU Leuven Library; 1999. Available from: https://bib.kuleuven.be/files/ebib/jaarverslagen/ROCHE_1999.pdf. Accessed 11 Dec 2019.
   Google Scholar
• OFX. Yearly average exchange rates 2019. Available from: https://www.ofx.com/en-au/forex-news/historical-exchange-rates/yearly-average-rates/.
   Google Scholar
• European Patent Register, EP0590058 (Genentech, Humanized heregulin antibody). Munich. 2004. https://register.epo.org/application?number=EP92914220&tab=main. Accessed 11 Dec 2019.
   Google Scholar
• Swiss Federation Institute of Intellectual Property, Supplementary Protection Certificate, C00590058/01 (Genentech, Humanized heregulin antibody). Bern. 2005. https://www.swissreg.ch/srclient/en/spc/C00590058/01. Accessed 11 Dec 2019.
   Google Scholar
• The National Industrial Property of France (INPI), CCP de médicament (SPC), FR04C0007 (Genentech, Humanized heregulin antibody). Paris. 2010. https://bases-brevets.inpi.fr/en/document-en/FR04C0007.html. Accessed 11 Dec 2019.
   Google Scholar
• Intellectual Property Office of the United Kingdom, Supplementary Protection Certificate, SPC/GB04/015 (Genentech, Humanized heregulin antibody). UK. Newport.2012. https://www.ipo.gov.uk/p-find-spc-bypatent-results.htm?number=EP0590058. Accessed 11 Dec 2019.
   Google Scholar
• Pollack A. Roche agrees to buy Genentech for $46.8 billion. New York: New York Times; 2009.
   Google Scholar
• Human Rights Council. Resolution: Access to Medicines in the Context of the Right of Everyone to the Highest Attainable Standard of Physical and Mental Health. A/HRC/RES/12/24. 2009.
   Google Scholar
• United Nations. Report of the United Nations secretary-General’s high-level panel on access to medicines. 2016.
   Google Scholar
• World Health Organization. Medicines shortages: global approaches to addressing shortages of essential medicines in health systems. Drug Inf. 2016;30:181–185.
   Google Scholar
• Hirschler B. How drugmakers face global push back on high prices. New York: Reuters; 2017.
   Google Scholar
• Iyengar Swathi, Tay-Teo Kiu, Vogler Sabine, Beyer Peter, Wiktor Stefan, de Joncheere Kees, et al. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLOS Medicine. 2016;13:e1002032. https://doi.org/10.1371/journal.pmed.1002032. Accessed 11 Dec 2019.
   PubMed Web of Science ®Google Scholar
• Mouterde Anne-Laure, Bocquet François, Fusier Isabelle, Paubel Pascal. Hepatitis C: how has France limited the expenses related to new treatments? Expert Review Pharmacoeconomics & Outcomes Research. 2016;16:655–657. https://doi.org/10.1080/14737167.2016.1247696. Accessed 11 Dec 2019.
   PubMed Web of Science ®Google Scholar
• Inspection Générale des Affaires Sociales. Rapport: Evaluation medico-économique en santé 2014 No 2014-066R.
   Google Scholar
• Ministère de la Solidarité et de la Santé. Commmuniqué – Accès universel aux traitements contre l’hépatite C: Marisol Touraine obtient une baisse de prix significative. 2016. Available from: https://solidarites-sante.gouv.fr/archives/archives-presse/archives-communiques-de-presse/article/acces-universel-aux-traitements-contre-l-hepatite-c-marisol-touraine-obtient. Accessed 11 Dec 2019.
   Google Scholar
• Le Figaro. Un médicament efficace contre l’hépatite C vient d’être autorisé à la vente en pharmacie. Paris: Le Figaro; 2018.
   Google Scholar
• Hépatite C. Les médicaments de Gilead bientôt disponibles en pharmacie. Paris: BFMTV; 2018.
   Google Scholar
• Preda Carmen M, Popescu Corneliu P, Baicus Cristian, Voiosu Theodor A, Manuc Mircea, Pop Corina Silvia, et al.. Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis. Liver International. 2018;38:602–610. https://doi.org/10.1111/liv.13550. Accessed 11 Dec 2019.
   PubMed Web of Science ®Google Scholar
• Bocci M. Via libera all ‘acquisto dei generici all’estero. Rome: la Repubblica; 2017.
   Google Scholar
• Cullen P. Hepatitis C patients unable to get drugs due to funding problems. Dublin: Irish Times; 2017.
   Google Scholar
• Patent Opposition Database. Available from: https://www.patentoppositions.org/en/drugs/sofosbuvir. Accessed 11 Dec 2019.
   Google Scholar
• Médecins Sans Frontières. Press Release: MSF secures lower price for generic hepatitis C treatment. Geneva; 2017. Available from: https://www.msf.org/msf-secures-lower-price-generic-hepatitis-c-treatment. Accessed 11 Dec 2019.
   Google Scholar
• Médecins Sans Frontières. Press release: Appeal lodged against decision to uphold Gilead’s patent on hepatitis C drug. Paris; 2018. Available from: https://www.msf.org/appeal-lodged-against-decision-uphold-gileads-patent-hepatitis-c-drug. Accessed 11 Dec 2019.
   Google Scholar
• World Health Organization. WHO implementation tool for pre-exposure prophylaxes (PrEP) of HIV infection. Geneva: Module 6: Pharmacists; 2017.
   Google Scholar
• World Intellectual Property Organization, Patentscope, WO9905150 (Gilead. Nucleotide analog composition and synthesis method). Geneva. 1999. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO1999005150&_cid=P11-K41HSV-36659-1. Accessed 11 Dec 2019.
   Google Scholar
• World Intellectual Property Organization, Patentscope, WO9111186 (Gilead. Method and compositions for the synthesis of Bch-189 and related compounds). Geneva.1991. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO1991011186&_cid=P11-K41HW3-37409-1. Accessed 11 Dec 2019.
   Google Scholar
• Pelé S, Thill-Tayara M, Schaffner M, Mitouard S, Devinant C. Combination of active ingredients - scope of protection - Gilead: Lexology; 2018. Available from: https://www.lexology.com/library/detail.aspx?g=dba23973-b2d2-4949-8e79-4b73415d8a55. Accessed 11 Dec 2019.
   Google Scholar
• Biogaran v Gilead. RG 17/09565: Paris Court of First Instance; 2018.
   Google Scholar
• The SPC Blog. France - Paris Court of First Instance nullifies Truvada SPC. 2018. Available from: http://thespcblog.blogspot.com/2018/05/france-paris-court-of-first-instance.html. Accessed 11 Dec 2019.
   Google Scholar
• The SPC Blog. Germany - Gilead’s SPC for Truvada nullified by the Federal Patent Court. 2018. Available from: http://thespcblog.blogspot.com/2018/05/germany-gileads-spc-for-truvada.html. Accessed 11 Dec 2019.
   Google Scholar
• Leavitt A, Lynch J. Gilead versus generics in Ireland – summary of case and observations from court. Dublin: Act-Up Dublin; 2017.
   Google Scholar
• Paul M. Gilead loss of generic HIV drug battle a boost for gay community. Dublin: Irish Times; 2017.
   Google Scholar
• The SPC Blog. Denmark – Gilead successfully enforces its SPC for Truvada. 2018. Available from: http://thespcblog.blogspot.com/2018/03/denmark-gilead-successfully-enforces.html. Accessed 11 Dec 2019.
   Google Scholar
• Mepha Pharma AG vs. Gilead. O2017_001: Swiss Federal Patent Court; 2017.
   Google Scholar
• The SPC Blog. Switzerland - Truvada and moving away from the “infringement test” for future SPCs for combination products. 2018. Available from: http://thespcblog.blogspot.com/2018/06/switzerland-truvada-and-moving-away.html. Accessed 11 Dec 2019.
   Google Scholar
• Gilead vs. Mylan. C/17/00048: Brussels Court of Commerce; 2017.
   Google Scholar
• Teva and others vs. Gilead. [2017] EWHC 13 (Pat): England and Wales High Court (Patent Court); 2017.
   Google Scholar
• Boulet P. CJEU ruling on Truvada recalls ‘evergreening’ goes against public health interests: Mediccines law & Policy 2018. Available from: https://medicineslawandpolicy.org/2018/09/cjeu-ruling-on-truvada-recalls-evergreening-goes-against-public-health-interests/. Accessed 11 Dec 2019.
   Google Scholar
• European Centre for Disease Prevention and Control. Evidence brief: Pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2016.
   Google Scholar
• Teva vs. Gilead. C-121-17: Court of Justice of the European Union; 2018.
   Google Scholar
• Medicijnkosten. Zorgintituut Nederland. Available from: https://www.medicijnkosten.nl.
   Google Scholar
• Vergoedbare geneesmiddelen. Riziv. Available from: http://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/nl/Public/ProductSearch.
   Google Scholar
• British National Formulary. Medicines Complete, The Royal Pharmaceutical Society. Available from: https://about.medicinescomplete.com/#/content/bnf/_180330626?hspl=truvada#DMD9098011000001105.
   Google Scholar
• Danish Medicines Agency. Database Medicinpriser.dk. Available from: https://medicinpriser.dk/default.aspx.
   Google Scholar
• Legemiddelsøk. Norwegian Medicines Agency. Available from: https://www.legemiddelsok.no.
   Google Scholar
• Fiche de presentation Truvada. Ministère des Affaires Sociales et de la Santé. Available from: http://medicprix.sante.gouv.fr/medicprix/detailPresentation.do?parameter=afficherPresDetail&idPresentation=49800.
   Google Scholar
• ABDATA: Pharma-Daten-Service. Mediengruppe Deutscher Apotheker. Available from: http://abdata.de/datenangebot/abda-datenbank/.
   Google Scholar
• Arzneimitteldatenbank. Arznei-telegramm®. Available from: https://www.arznei-telegramm.de/01atd_info1.php3.
   Google Scholar
• Medikamentensuche. Mymedi.ch. Available from: https://www.mymedi.ch/.
   Google Scholar
• IPU product file. Irish Pharmacy Union. Dublin. Available from: https://ipu.ie/home/ipu-product-file/.
   Google Scholar
• Pharmaceutisch Weekblad. PrEP verkrijgbaar voor € 50 per maand. Den Haag: PW04; 2018.
   Google Scholar
• Wilson C. Massive drop in London HIV rates may be due to internet drugs. London: New Scientist; 2018.
   Google Scholar
• La PrEP: AIDES; 2018. Available from: https://www.aides.org/prep. Accessed 11 Dec 2019.
   Google Scholar
• PrEP will soon be available for 50 Euros in Germany, starting in seven cities Berlin: Deutsche Aidshilfe; 2017. Available from: https://www.aidshilfe.de/meldung/prep-will-soon-available-50-euros-germany-starting-seven-cities. Accessed 11 Dec 2019.
   Google Scholar
• Halpin H. A HIV prevention drug is being made available to Irish pharmacies at a 70% cheaper cost. Dublin: TheJournal.ie; 2017.
   Google Scholar
• Hiv-preventiepil PrEP na jarenlange lobby in Nederland vergoed, Aidsfonds mist urgentie bij minister Amsterdam: AT5; 10 juli 2018. Available from: http://www.at5.nl/artikelen/184165/hiv-preventiepil-prep-na-jarenlange-lobby-in-nederland-vergoed-aidsfonds-mist-urgentie-bij-minister. Accessed 11 Dec 2019.
   Google Scholar
• Geneesmiddel in PrEp om een HIV-infectie te voorkomen: terugbetaling vanaf 1 juni 2017: Riziv; 2017. Available from: http://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetalen/specialiteiten/wijzigingen/Paginas/geneesmiddelen-PrEp-HIV.aspx#.W0jMyGePXXo. Accessed 11 Dec 2019.
   Google Scholar
• PrEP on the NHS London: I want PrEP now. Available from: https://www.iwantprepnow.co.uk/prep-on-the-nhs. Accessed 11 Dec 2019.
   Google Scholar
• Collis H. England’s HIV prevention trial to test generic Truvada. Brussels: Politico; 2017.
   Google Scholar
• Duffy N. Norway to provide free HIV-preventing PrEP drugs to at-risk gay men. London: Pink News; 2016.
   Google Scholar
• Schwinn M. HIV-prophylaxe soll krankenkassenleistung werden. Munich: Süddeutsche Zeitung; 2018.
   Google Scholar
• PrEP Zürich: Aide Suisse Contre le Sida. Available from: https://www.aids.ch/en/faq/protection-risk/prep.php. Accessed 11 Dec 2019.
   Google Scholar
• Finnegan B. More affordable PrEP to be made available in Irish pharmacies. Dublin: GCN; 2017.
   Google Scholar
• XE. Available from: www.xe.com.
   Google Scholar
• Coleman R, Prins M. Options for affordable pre-exposure prophylaxis (PrEP) in national HIV prevention programmes in Europe. Euro Surveill. 2017;22. https://doi.org/10.2807/1560-7917.ES.2017.22.42.17-00698. Accessed 11 Dec 2019.
   Google Scholar
• Butterworth B. Europe’s largest sexual health clinic launches PrEP service due to huge demand. London: Pink News; 2018.
   Google Scholar
• Neves V. The theory of social costs of K. William Kapp: some notes on Sebastian Berger’s the social costs of neoliberalism. Forum Soc Econ. 2018:1–13. https://doi.org/10.1080/07360932.2018.1481127. Accessed 11 Dec 2019.
   Google Scholar
• Choe S-C, Kim W. Globalization and Urbanization in the Republic of Korea. In: Yusuf S, Evenett S, Wu W, editors. Facets of Globalization International and Local Dimensions of Development: World Bank Paper n°415; 2001.
   Google Scholar
• Bridy A. Trade secret prices and high-tech devices: how medical device manufacturers are seeking to sustain profits by Propertizing prices. Tex Intell Prop LJ. 2009;17:187-222.
   Google Scholar